2 unchanged sentences
Based upon that evaluation, the Principal Executive Officer and the Principal Financial Officer concluded that the Company’s disclosure controls and procedures were effective.
−Removed: During the quarter ended December 31, 2021, the Company continued to transition certain support services from Pfizer, as well as certain subsidiaries, to a new ERP system.
−Removed: The Company has modified and will continue to modify its internal controls relating to its business and financial processes throughout the transition period, which is expected through the end of calendar year 2022.
−Removed: While the Company believes that this new system and the related changes to internal controls will ultimately strengthen its internal control over financial reporting, there are inherent risks in implementing any new ERP system and the Company has evaluated and tested control changes in order to provide Management’s Report on Internal Control over Financial Reporting for the year ended December 31, 2021.
+Added: Management identified the following change in the Company’s internal control over financial reporting (“ICFR”) that occurred during the quarter that has materially affected, or is reasonably likely to materially affect, the Company’s ICFR.
+Added: During the quarter ended December 31, 2022, the Company substantially completed its transition of certain support services from Pfizer, as well as certain subsidiaries, to a new ERP system.
+Added: The Company has modified and implemented new controls and procedures relating to its business and financial processes throughout the transition period.
+Added: While the Company believes that this new system and the related changes to internal controls will ultimately strengthen its ICFR, there are inherent risks in implementing any new ERP system and the Company will continue to evaluate and monitor the effectiveness of the related controls in subsequent periods.
Management’s Report on Internal Control over Financial Reporting is on page 76, which is incorporated herein by reference.
82 unchanged sentences
with the SEC on November 19, 2020, and incorporated herein by reference.
+Added: Transaction Agreement, dated as of February 27, 2022, by and among Biocon Biologics Limited and Viatris Inc., filed as Exhibit 2.1 to the Report on Form 8-K filed by Viatris Inc.
+Added: with the SEC on February 28, 2022, and incorporated herein by reference.^
+Added: Amendment No.
+Added: 1 to Transaction Agreement, dated as of November 28, 2022, by and between Biocon Biologics Limited and Viatris Inc., filed as Exhibit 2.1 to the Report on Form 8-K filed by Viatris Inc.
+Added: with the SEC on November 29, 2022, and incorporated herein by reference.^
Amended and Restated Certificate of Incorporation of Upjohn Inc., effective as of November 13, 2020, filed as Exhibit 3.1 to the Report on Form 8-K filed by Viatris Inc.
27 unchanged sentences
with the SEC on November 19, 2020, and incorporated herein by reference.
−Removed: Indenture, dated as of December 9, 2015, among Mylan N.V., as issuer, Mylan Inc., as guarantor, and The Bank of New York Mellon, as trustee, filed as Exhibit 4.1 to the Report on Form 8-K filed by Mylan N.V.
−Removed: with the SEC on December 15, 2015, and incorporated herein by reference.
−Removed: First Supplemental Indenture dated November 16, 2020, by and among Viatris Inc., Utah Acquisition Sub Inc., Mylan II B.V., Mylan Inc.
−Removed: and the Bank of New York Mellon, as trustee, to the Indenture dated December 9, 2015, by and among Mylan N.V., Mylan Inc.
−Removed: and the Bank of New York Mellon, as trustee, filed as Exhibit 4.3 to the Report on Form 8-K/A filed by Viatris Inc.
−Removed: with the SEC on November 19, 2020, and incorporated herein by reference.
Indenture, dated as of June 9, 2016, among Mylan N.V., as issuer, Mylan Inc., as guarantor, and The Bank of New York Mellon, as trustee, filed as Exhibit 4.1 to the Report on Form 8-K filed by Mylan N.V.
92 unchanged sentences
as Exhibit 10.1(l) to Form 10-K for the fiscal year ended December 31, 2015, and incorporated herein by reference.*
−Removed: Form of Performance-Based Restricted Stock Unit Award Agreement under the Mylan N.V.
−Removed: 2003 Long-Term Incentive Plan for Rajiv Malik for awards granted on or after February 21, 2018, filed by Mylan N.V.
−Removed: as Exhibit 10.2 to Form 10-Q for the quarter ended March 31, 2018, and incorporated herein by reference.*
−Removed: Form of Performance-Based Restricted Stock Unit Award Agreement under the Mylan N.V.
−Removed: 2003 Long-Term Incentive Plan for awards granted on or after February 21, 2018, filed by Mylan N.V.
−Removed: as Exhibit 10.3 to Form 10-Q for the quarter ended March 31, 2018, and incorporated herein by reference.*
Form of Stock Option Agreement under the Mylan N.V.
7 unchanged sentences
as Exhibit 10.6 to Form 10-Q for the quarter ended March 31, 2019, and incorporated herein by reference.*
−Removed: Form of Restricted Stock Unit Award Agreement under the Mylan N.V.
−Removed: 2003 Long-Term Incentive Plan for independent directors for awards granted on or after March 2, 2020, filed by Mylan N.V.
−Removed: as Exhibit 10.1 to Form 10-Q for the quarter ended March 31, 2020, and incorporated herein by reference.*
Form of Stock Option Agreement under the Mylan N.V.
40 unchanged sentences
as Exhibit 10.57 to Form 10-K for the fiscal year ended December 31, 2013, and incorporated herein by reference.*
−Removed: Executive Employment Agreement, entered into on April 15, 2020, by and between Mylan N.V., Mylan Inc.
−Removed: and Robert J.
−Removed: Coury, filed by Mylan N.V.
−Removed: as Exhibit 10.3 to Form 10-Q for the quarter ended March 31, 2020, and incorporated herein by reference.*
Third Amended and Restated Executive Employment Agreement, entered into on February 25, 2019, and effective as of April 1, 2019, by and between Mylan Inc.
3 unchanged sentences
and Anthony Mauro, filed as Exhibit 10.21(b) to Form 10-K for the fiscal year ended December 31, 2018, and incorporated herein by reference.*
−Removed: Letter Agreement, dated June 3, 2016, among Mylan N.V., Mylan Inc., and Robert J.
−Removed: Coury, filed by Mylan N.V.
−Removed: as Exhibit 10.5 to Form 10-Q for the quarter ended June 30, 2016, and incorporated herein by reference.*
−Removed: Form of Waiver Letter with respect to Specified Award Agreements by and between Mylan N.V.
−Removed: and Rajiv Malik, February 23, 2017, filed by Mylan N.V.
−Removed: as Exhibit 10.4 to Form 10-Q for the quarter ended March 31, 2017, and incorporated herein by reference.
2007 Supplemental Health Insurance Plan for Certain Key Employees of Mylan Laboratories Inc., adopted as of January 29, 2007, filed by Mylan N.V.
96 unchanged sentences
JoEllen Lyons Dillon
−Removed: /s/ NEIL DIMICK Director
+Added: /s/ ELISHA FINNEY Director
+Added: Elisha Finney
/s/ MELINA HIGGINS Director
6 unchanged sentences
PARRISH Director
−Removed: /s/ IAN READ Director
+Added: /s/ SCOTT SMITH Director
/s/ PAULINE VAN DER MEER MOHR Director
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.